Consider fertility-preserving medications when treating adenomyosis
article
OA: closed
CC0
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
Levonorgestrel-releasing intrauterine systems and dienogest are considered first-line fertility-preserving medical treatments for adenomyosis symptoms, while GnRH agonists are a second-line option.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (42)
- A controlled clinical trial comparing potent progestins, LNG‐IUS and dienogest, for the treatment of women with adenomyosis via openalex
- Adenomyosis pathogenesis: insights from next-generation sequencing via openalex
- Adverse symptoms during short‐term use of ulipristal acetate in women with uterine myomas and/or adenomyosis via openalex
- A New Therapy for Pelvic Endometriosis and Uterine Adenomyosis: Local Effect of Vaginal and Intrauterine Danazol Application via openalex
- A pilot study on the off-label use of valproic acid to treat adenomyosis via openalex
- Aromatase and endometriosis: estrogens play a role via openalex
- Comparison of combined transcervical resection of the endometrium and levonorgestrel-containing intrauterine system treatment versus levonorgestrel-containing intrauterine system treatment alone in women with adenomyosis: a prospective clinical trial. via openalex
- Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial via openalex
- Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial via openalex
- Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis via openalex
- Current and Prospective Treatment of Adenomyosis via openalex
- Danazol Suspension Injected into the Uterine Cervix of Patients with Adenomyosis and Myoma via openalex
- Dienogest via openalex
- Effect of pretreatment with a levonorgestrel-releasing intrauterine system on IVF and vitrified–warmed embryo transfer outcomes in women with adenomyosis via openalex
- Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis. via openalex
- Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age via openalex
- Elevated Immunoreactivity against Class I Histone Deacetylases in Adenomyosis via openalex
- Fertility-Sparing Treatment of Adenomyosis in Patients With Infertility: A Systematic Review of Current Options via openalex
- Guideline No. 437: Diagnosis and Management of Adenomyosis via openalex
- Intralipid infusion therapy as an adjunct treatment in women experiencing adenomyosis-related infertility via openalex
- Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial via openalex
- Long‐term dienogest administration in patients with symptomatic adenomyosis via openalex
- Novel conservative medical therapy for uterine adenomyosis with a danazol-loaded intrauterine device via openalex
- OP30.04: Changes in the sonographic characteristics of adenomyosis after treatment with ulipristal acetate via openalex
- Pituitary suppression with GnRH agonists before ART may be insufficient to treat women with severe adenomyosis via openalex
- Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest via openalex
- Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies via openalex
- The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis via openalex
- Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis via openalex
- Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy via openalex
- Ulipristal acetate use in adenomyosis: A randomized controlled trial via openalex
- Vaginal bromocriptine for treatment of adenomyosis: Impact on magnetic resonance imaging and transvaginal ultrasound via openalex
- Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: A pilot study via openalex
- W2739010978 via openalex
- W3203416324 via openalex
- W2109711640 via openalex
- W4365810788 via openalex
- W2079078286 via openalex
- W1925466818 via openalex
- W4387640260 via openalex
- W6638159739 via openalex
- W6784688324 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK